Oncolytics Biotech Files 6-K Financial Report
Ticker: ONCY · Form: 6-K · Filed: Mar 7, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, 6-K, foreign-private-issuer
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH (ONCY) filed its 6-K financial report on March 7, 2024.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on March 7, 2024, reporting its financial results. The filing is for a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive offices are located in Calgary, Alberta, Canada.
Why It Matters
This filing provides investors with updated financial information for Oncolytics Biotech Inc., crucial for assessing the company's performance and making investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- March 7, 2024 (date) — Filing Date
- Calgary, Alberta, Canada (location) — Principal Executive Offices
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
When was this filing submitted?
The filing was submitted on March 7, 2024.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
The principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Does Oncolytics Biotech Inc. file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under Form 20-F.
What is the SIC code for Oncolytics Biotech Inc.?
The Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-03-07 16:06:03
Filing Documents
- form6kq4-2023financialresu.htm (6-K) — 18KB
- oncyq42023.htm (EX-99.1) — 169KB
- 0001129928-24-000014.txt ( ) — 188KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date March 7, 2024 Kirk Look Chief Financial Officer